Add to ORKGRare tumors, when considered as a group, represent a significant burden to society as they may account for up to 25 % of the mortal-ity by cancer in nations like the United States. In contrast with the current scenario in highly incident cancer types, little progress has been achieved in the treatment of the most rare can-cers. The reasons for this apparent stagnation are mostly intrinsic to logistical difficulties in performing large clinical trials in rare diseases and will be addressed further in this article. Because both cancer incidence and clinical research are booming in emerging nations, we also aim to address the current and future rol
In recent years, China's anti-tumor drugs has shown a continuous growth trend, and the activity of a...
To date, the Rare Cancer Network (RCN) has initiated more than 90 studies and 54 peer-reviewed publi...
PURPOSE: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Canc...
Rare cancers are not rare at all: they account for more than 20 % of all cancers and affect more tha...
Rare tumor research presents many challenges. Large, randomized clinical trials are often impractica...
Introduction: Rare cancers together account for about 22% of new cancer diagnoses each year, which i...
Rare tumor research presents many challenges. Large, randomized clinical trials are often impractica...
More than 50 % of all gynecologic cancers can be classified as rare tumors (defined as an incidence ...
Rare cancers, as a collective, account for approximately one-quarter of all cancer diagnoses and dea...
Rare childhood cancers have not benefited to the same extent from the gains that have been made for ...
The past three decades have seen rapid improvements in the diagnosis and treatment of most cancers a...
Purpose: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cance...
Purpose: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cance...
The widespread incidence and effects of cancer have led to a growing development in cancer preventio...
To date, the Rare Cancer Network (RCN) has initiated more than 90 studies and 54 peer-reviewed publi...
In recent years, China's anti-tumor drugs has shown a continuous growth trend, and the activity of a...
To date, the Rare Cancer Network (RCN) has initiated more than 90 studies and 54 peer-reviewed publi...
PURPOSE: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Canc...
Rare cancers are not rare at all: they account for more than 20 % of all cancers and affect more tha...
Rare tumor research presents many challenges. Large, randomized clinical trials are often impractica...
Introduction: Rare cancers together account for about 22% of new cancer diagnoses each year, which i...
Rare tumor research presents many challenges. Large, randomized clinical trials are often impractica...
More than 50 % of all gynecologic cancers can be classified as rare tumors (defined as an incidence ...
Rare cancers, as a collective, account for approximately one-quarter of all cancer diagnoses and dea...
Rare childhood cancers have not benefited to the same extent from the gains that have been made for ...
The past three decades have seen rapid improvements in the diagnosis and treatment of most cancers a...
Purpose: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cance...
Purpose: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cance...
The widespread incidence and effects of cancer have led to a growing development in cancer preventio...
To date, the Rare Cancer Network (RCN) has initiated more than 90 studies and 54 peer-reviewed publi...
In recent years, China's anti-tumor drugs has shown a continuous growth trend, and the activity of a...
To date, the Rare Cancer Network (RCN) has initiated more than 90 studies and 54 peer-reviewed publi...
PURPOSE: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Canc...